secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001213900-23-056454
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TradeUP Acquisition Corp. to liquidate trust account into cash, announces July 31 special meeting for Estrella merger
--------------------------------------------------------------------------------

- Trust account to liquidate U.S. treasury obligations and money market funds on July 14, 2023; proceeds held in cash to avoid Investment Company Act classification.
- Proxy statement/prospectus for business combination with Estrella Biopharma declared effective July 11, 2023; special meeting set for July 31, 2023.
- Extension meeting on July 17, 2023 to vote on extending combination deadline to July 14, 2024; redemption price ~$10.51/share if extension approved.
- Public stockholders may redeem shares at ~$10.51 in connection with extension (deadline July 13) or at expected ~$0.05 higher for merger (deadline July 27).
- If extension approved, additional $0.05 per share deposited monthly into trust for each non-redeemed share beyond July 19, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390023056454/0001213900-23-056454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390023056454/ea181670-8k_tradeupacq.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-056454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer